Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.

Oncogene - 20 Aug 1998

Guo X Y, Cuillerot J M, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier C, Greenberger J, Colombowala I, Deisseroth A B

Abstract excerpt

We first showed that the introduction of a bcr-abl transcription unit into the 32D murine myeloid cell line (P210bcrabl32D) converts this cell line from an IL3 dependent cell line to an IL3 growth independent cell line. We next cloned a fragment of the bcr-abl cDNA, which codes for the bcr oligomerization domain and neighboring regions. To test for a transformation inhibitory effect of this oligomerization...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Division
Share to Cell Line, Transformed

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phenotype

Share to Plasmids

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Transfection

Source

Identifiers

PMID: 9779999
DOI: 10.1038/sj.onc.1201999

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.PMID 9779999Read ↗

A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.Semantic proximity Read ↗

Structure of the Bcr-Abl oncoprotein oligomerization domain.Semantic proximity Read ↗

Presence of P210bcrabl is associated with decreased expression of a beta chemokine C10 gene in a P210bcrabl-positive myeloid leukemia cell line.Semantic proximity Read ↗

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.Semantic proximity Read ↗

Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.Semantic proximity Read ↗

Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.Semantic proximity Read ↗

Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptideSemantic proximity Read ↗

Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.Semantic proximity Read ↗

Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.Semantic proximity Read ↗

Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense OligodeoxynucleotidesSemantic proximity Read ↗

Specific inhibition of bcr-abl gene expression by small interfering RNASemantic proximity Read ↗

Tyrosine Kinase Activity and Transformation Potency of <i>bcr-abl</i> Oncogene ProductsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.